Oncothyreon Inc. (Nasdaq: ONTY) reported positive preliminary data from two
ongoing Phase 1b studies of ONT-380 to treat metastatic breast cancer sending the stock price up 31 cents to close at $2.02.
Oncothyreon reports positive data
December 12, 2014 at 16:09 PM EST